CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference

MINNEAPOLIS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, Dec. 3, 2025. The fireside chat is scheduled at 2:00 p.m. (ET) the same day via webcast.

GlobeNewsWire • Nov 19, 2025

CVRx, Inc. (CVRX) Q3 2025 Earnings Call Transcript

CVRx, Inc. ( CVRX ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Kevin Hykes - President, CEO & Director Jared Oasheim - Chief Financial Officer Conference Call Participants Mike Vallie - Westwicke Partners, LLC John Young - Canaccord Genuity Corp., Research Division Samantha Munoz - Piper Sandler & Co., Research Division Rohin Patel - JPMorgan Chase & Co, Research Division Max Smock Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division Presentation Operator Greetings, and welcome to the CVRx Third Quarter 2025 Earnings Conference Call. As a reminder, this conference is being recorded.

Seeking Alpha • Nov 6, 2025

CVRx (CVRX) Reports Q3 Loss, Beats Revenue Estimates

CVRx (CVRX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.57 per share a year ago.

Zacks Investment Research • Nov 6, 2025

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2025 financial and operating results after market close on Wednesday, Nov. 5, 2025. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1- 877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.

GlobeNewsWire • Oct 22, 2025

CVRx (CVRX) Q2 Revenue Jumps 15%

CVRx (CVRX) Q2 Revenue Jumps 15%

The Motley Fool • Aug 5, 2025

CVRx, Inc. (CVRX) Q2 2025 Earnings Call Transcript

Call Start: 16:30 January 1, 0000 5:09 PM ET CVRx, Inc. (NASDAQ:CVRX ) Q2 2025 Earnings Conference Call August 04, 2025, 04:30 PM ET Company Participants Jared Oasheim - Chief Financial Officer Kevin Hykes - President, CEO & Director Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C., Research Division Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division John Edward Young - Canaccord Genuity Corp., Research Division Rohin Kirit Patel - JPMorgan Chase & Co, Research Division Ross Everett Osborn - Cantor Fitzgerald & Co., Research Division Samantha Munoz - Piper Sandler & Co., Research Division Michael Vallie - Unidentified Company Operator Good afternoon, ladies and gentlemen.

Seeking Alpha • Aug 4, 2025

CVRx Reports Second Quarter 2025 Financial and Operating Results

MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2025.

GlobeNewsWire • Aug 4, 2025

CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates

CVRx (CVRX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.65 per share a year ago.

Zacks Investment Research • Aug 4, 2025

CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference

MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast.

GlobeNewsWire • Jul 29, 2025

CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Jul 28, 2025